Nature Reviews Cardiology, Published online: 22 January 2026; doi:10.1038/s41569-026-01256-0Treatment with low-dose IL-2 increases regulatory T cell numbers and reduces arterial inflammation in patients with an acute coronary syndrome and residual systemic inflammation compared with placebo, according to findings from the IVORY trial.